Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The company’s 50 day moving average is $49.62 and its two-hundred day moving average is $54.12.

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

The Halozyme/Roche relationship dates back to the 2006, and has already produced two subcutaneous versions of existing Roche blockbusters – Herceptin and Rituxan/MabThera.

JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $7.00.Invest ...

In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

For 25 years, it was Joe Panetta’s job to tell the story of San Diego’s biotechnology community to the world. And the job ...

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article. BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Riad Sattouf’s saga of his parents’ failed bicultural marriage, with its harsh depiction of life in rural Syria, has become a literary sensation. By Richard Fausset A popular TV host ...

Hundreds of truckloads of food, fuel and other supplies have arrived in Gaza each day since the cease-fire took effect. But the need is vast after 15 months of war. By Vivian Yee and Bilal ...